CSSPF (NIOX Group) 3-Year Share Buyback Ratio: 0.10% (As of Dec. 2025)


CSSPF NIOX Group PLC CSSPF
77 GF Score
Price $0.75
GF Value $1.21
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is NIOX Group 3-Year Share Buyback Ratio?

NIOX Group CSSPF 77 3-Year Share Buyback Ratio is 0.10 as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 614 Medical Devices & Instruments companies, NIOX Group ranks better than 80.46% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. NIOX Group's current 3-Year Share Buyback Ratio was 0.10%.

The historical rank and industry rank for NIOX Group's 3-Year Share Buyback Ratio or its related term are showing as below:

CSSPF' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -20.7   Med: -5.7   Max: 1.7
Current: 0.1

During the past 13 years, NIOX Group's highest 3-Year Share Buyback Ratio was 1.70%. The lowest was -20.70%. And the median was -5.70%.

CSSPF's 3-Year Share Buyback Ratio is ranked better than
80.46% of 614 companies
in the Medical Devices & Instruments industry
Industry Median: -2.65 vs CSSPF: 0.10

NIOX Group (OTCPK:CSSPF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


NIOX Group 3-Year Share Buyback Ratio Related Terms


CSSPF vs ABT, SYK, MDT: 3-Year Share Buyback Ratio Comparison

For the Medical Devices subindustry, NIOX Group's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NIOX Group 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where NIOX Group's 3-Year Share Buyback Ratio falls into.


CSSPF
77GF Score
NIOX Group PLC CSSPF
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NIOX Group 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of 0.10 mean?
NIOX Group (CSSPF) has a 3-Year Share Buyback Ratio of 0.10 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #120 out of 614 companies in the Medical Devices & Instruments industry, placing it in the top 19.5%.
Is NIOX Group's 3-Year Share Buyback Ratio too high?
NIOX Group's current 3-Year Share Buyback Ratio is 0.10. Based on the distribution chart, NIOX Group ranks #120 out of 614 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's 3-Year Share Buyback Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #120 out of 614 companies for 3-Year Share Buyback Ratio. This places NIOX Group in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for NIOX Group and its competitors. NIOX Group's current 3-Year Share Buyback Ratio is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current 3-Year Share Buyback Ratio is 0.10. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For NIOX Group (CSSPF), the current 3-Year Share Buyback Ratio is 0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NIOX Group (CSSPF) Overvalued in 2026?

Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued. The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21. GuruFocus considers NIOX Group to be Significantly Undervalued.

Key valuation signals for CSSPF:

  • 3-Year Share Buyback Ratio: 0.10
  • GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NIOX Group Business Description

Other Exchanges NIOXl:UKNIOX:UK82C:Germany
Address 1 Robert Robinson Avenue, Magdalen Centre, The Oxford Science Park, Oxford, GBR, OX4 4GA
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score

Get the complete analysis for CSSPF

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price
$1.21
GF Value